Knight Therapeutics Inc. (OTC:KHTRF), a specialty pharmaceutical company operating across the Americas, focuses on acquiring, licensing, and marketing pharmaceutical products. Competing with other pharmaceutical firms in the region, it strives to expand its market presence and product offerings. On November 6, 2025, KHTRF reported its earnings, revealing a challenging quarter.
KHTRF's earnings per share (EPS) for the third quarter of 2025 were -$0.02, missing the estimated EPS of -$0.005. This indicates that the company earned less per share than analysts expected.
The company's actual revenue of approximately $88 million fell short of the estimated $107 million. However, the increase in revenues from the previous year shows progress. The gross margin decreased slightly to 46% from 49% last year, mainly due to contributions from the Paladin and Sumitomo deals. This indicates that while revenues increased, the cost of goods sold also rose.
KHTRF's financial metrics reveal interesting insights. The price-to-sales ratio of 1.56 and enterprise value to sales ratio of 1.63 reflect the company's valuation in relation to its sales. These ratios indicate that the stock is valued at about 1.56 times its sales. The company's debt-to-equity ratio is 0.14, indicating a low level of debt compared to its equity. This suggests financial stability and a lower risk of financial distress.
Additionally, the current ratio of 2.47 shows that KHTRF has a strong ability to cover its short-term liabilities with its short-term assets, ensuring liquidity. Despite the challenges, the company remains financially sound with growth prospects.
